Since 1917, tax filers with children have received ever-increasing federal income tax benefits. The tax benefits include deductions for each child or other dependent, lower tax brackets for head-of household filers compared to single filers with similar incomes, and tax credits for children and childcare expenses.
Matrix Global Advisors (MGA) today released a new report, “Potential Savings from Accelerating US Approval of Complex Generics,” by MGA founder and CEO Alex Brill.
Matrix Global Advisors (MGA) today released a new report, “Negative Economic Impact of Restricting Drug Rebates in Medicare Part D,” by MGA founder and CEO Alex Brill. The report looks at a July 2020 Executive Order on prescription drug rebates that invokes a proposed regulatory change President Trump withdrew a year earlier.
Matrix Global Advisors (MGA) today released a new report, “The Negative Economic Effects of Medicare Buy-In and Public Option Proposals,” by MGA founder and CEO Alex Brill.
Recent data show a small decline in opioid-related mortality following a decade during which opioid-related mortality more than doubled to nearly 53,000 in 2018. However, the aggregate statistics mask important spatial and temporal trends in the data. This report estimates nationwide, regional, and county-level economic costs associated with the opioid crisis.
Last October, a new controversy erupted over the progressivity of the American tax system. The brouhaha was prompted by a new book, The Triumph of Injustice, by economists Emmanuel Saez and Gabriel Zucman. In it, the authors claim that the highest-earning Americans’ tax rate has fallen below everyone else’s.
As the United States marks the tenth anniversary of the establishment of a biosimilars pathway, many experts express frustration that the US lags behind
Europe. A new white paper from Matrix Global Advisors carefully examines the US and European biosimilars markets and finds that the comparison between the markets is nuanced.
Matrix Global Advisors (MGA) today released a new report, “Shared Savings Demonstration for Biosimilars in Medicare: An Opportunity to Promote Biologic Drug Competition,” by MGA founder and CEO Alex Brill. The report identifies a unique opportunity in Medicare Part B to boost biosimilar utilization through the establishment of a shared savings demonstration model administered by the Centers for Medicare & Medicaid Services Innovation Center.
Based on MGA’s independent analysis, the Teva Global Economic Impact Report estimates Teva’s economic impact in 19 of the 60 countries in which Teva operates.
This report examines the BLOCKING Act and why it is a misguided attempt at promoting generic drug competition.